Agomab Therapeutics Director David R. Epstein Reports $103,500 Common Share Acquisition

PUBT · 3d ago
Agomab Therapeutics Director David R. Epstein Reports $103,500 Common Share Acquisition
  • Agomab Therapeutics director David R. Epstein purchased 15,000 common shares, raising his direct holdings to 40,000 shares.
  • Purchases comprised 5,000 shares each at $6.81, $6.91 and $6.98 per share.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agomab Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001445826-26-000018), on November 06, 2026, and is solely responsible for the information contained therein.